



**HAL**  
open science

## Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France

Damien Lanéelle, M. Dadon, I. Quere, S. Zuily, Joseph Emmerich,  
Marie-Antoinette Pietri-Sevestre, Guillaume Mahé

► **To cite this version:**

Damien Lanéelle, M. Dadon, I. Quere, S. Zuily, Joseph Emmerich, et al.. Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France. *JMV-Journal de Médecine Vasculaire*, 2021, 46 (2), pp.90-92. 10.1016/j.jdmv.2021.01.002 . hal-03164100

**HAL Id: hal-03164100**

**<https://hal.science/hal-03164100>**

Submitted on 29 Mar 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Letter to the editor

## Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France.

Short title: Discontinuation of vascular treatments during first wave of COVID-19 in France

Authors list: Damien Lanéelle<sup>1</sup>, Michel Dadon<sup>2</sup>, Isabelle Quere<sup>3</sup>, Stéphane Zuily<sup>4</sup>, Joseph Emmerich<sup>5</sup>, Marie-Antoinette Sevestre<sup>6</sup>, Guillaume Mahé<sup>7,8</sup>, on behalf the SFMV.

1: Department of Vascular Medicine, Inserm UMR 1075, CHU Caen Normandie, Caen, France

2: Vascular Explorations Center, 7 rue Chalgrin, 75116 Paris, France

3: Department of Vascular medicine, CHU Saint Eloi, University of Montpellier, Inserm CIC1001, InnoVTE, Montpellier, France.

4: University of Lorraine, Inserm UMR 1116, CHRU de Nancy, Vascular Medicine Division, Nancy, France.

5: University of Paris, Vascular Medicine, Groupe Hospitalier Paris Saint-Joseph, INSERM CRESS UMR 1153, Paris, France.

6: Department of Vascular Medicine, EA Chimère 7516, CHU Amiens Picardie 80054 Amiens cedex 1, France

7: Department of Vascular Medicine, CHU Rennes, 35033 Rennes Cedex 9, France

8: Université de Rennes 1, INSERM CIC 1414, 35033 Rennes Cedex 9, France

Correspondence to:

**Guillaume MAHE, MD-PhD**

Vascular Medicine and Investigation Department

INSERM CIC-1414. Pôle imagerie médicale et explorations fonctionnelles

Hôpital Pontchaillou, 2 rue Henri Le Guilloux. Rennes, F-35033. France

Tel: +33 (0)2 9928 4321

Fax: +33 (0)2 9928 4364

E-mail: maheguillaume@yahoo.fr

**Keywords:** Vascular medicine, Peripheral Artery Disease, Venous thromboembolic Disease, thromboprophylaxis, COVID-19, Vascular therapeutics

**Word Count:** 1280

**BACKGROUND:** Coronavirus disease 2019 (COVID-19) pandemic led to measures throughout Europe ranging from social distancing to widespread containment [1], which

could lead to discontinuation of treatment. In addition, several studies suggest an over-risk of venous thromboembolic disease associated with COVID-19, which has led the French [2] and international [3] learned societies to propose thromboprophylaxis in the most severe forms. Finally, controversies have emerged on the role of Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-2 receptor antagonists (ARB2) [4] which are daily treatments for many patients with peripheral artery disease who are themselves at risk of severe COVID-19 infection [5].

These different elements may have led to changes of vascular therapeutics during the COVID-19 epidemic in France; at the request of the French national agency of drugs this work aims to identify them.

**METHODS:** A 6 points questionnaire was proposed to patients during an out-patient consultation by vascular physicians who were members of the French Society of Vascular Medicine (SFMV). Physicians had previously received an e-mail request to participate by completing an online questionnaire (LimeSurvey® Software, Hamburg). Patients were informed of the objectives of the research and the anonymity of data collected. The estimated time for answering questions was two minutes. Anonymous data were centralized in a database hosted by the SFMV. Participation was unpaid. Quantitative results are expressed in mean  $\pm$  standard deviation and qualitative in percentage (%).

**RESULTS:** In May 2020, 1936 e-mails were sent to SFMV members. This resulted in the collection of completed questionnaires for 297 patients whose characteristics are shown in table 1. This survey identified 5% of treatment withdrawals. The treatments usually prescribed for chronic diseases, such as anti-platelet or statins for peripheral artery disease, were largely maintained (respectively 0.3% and 1.0% of discontinuation).

**DISCUSSION:** Other studies have investigated the impact of the pandemic on the management of patients, including a decrease in emergency hospitalizations [6] and immunomodulatory treatment interruptions [7], but to our knowledge this is the first report on vascular therapeutics follow-up during the COVID-19 pandemic. We found that 5% of patients stopped treatments in a sample of 297 patients. The circumstances of these discontinuations are unknown, but it can be assumed that some of them, such as those for VTE anticoagulants, may be secondary to the non-renewal of a prescription or the planned end of a short course of treatment. It should be noted that there has been no interruption of supply or shortage of these drugs in French pharmacies [8]. The initial controversy over ACE or ARB2 does not appear to have led to discontinuation of treatment and should not be further addressed in light of the results of the BRACE CORONA study, which found no significant difference in 30-day survival between discontinuation or continuation of ACE/ARB2 in patients hospitalized for COVID-19 [9]. Finally, it should be noted that the activity of vascular physicians was probably strongly impacted during this pandemic as suggested by a survey during the same period, using an identical questionnaire methodology filled out by volunteer vascular physicians, potentially subject to the same selection bias [10].

Regarding the limitations, this study was not able to evaluate the consequences of these therapeutic changes and the representativeness of patients with chronic vascular disease is not assured. Indeed, patient history was not systematically collected, the reason for consultation was unknown as well as the participation rate.

**CONCLUSION:** This survey did not identify major modification of vascular therapeutics during the COVID-19 pandemic first wave in patients followed by vascular physicians who were members of the SFMV.

Journal Pre-proof

## Référence

1. Guidelines for the implementation of non-pharmaceutical interventions against COVID-19. In: European Center for Disease Prevention and Control. <https://www.ecdc.europa.eu/en/publications-data/covid-19-guidelines-non-pharmaceutical-interventions>. Accessed 16 Nov 2020
2. Khider L, Soudet S, Laneelle D, Böge G, Bura-Rivière A, Constans J, et al. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19. *J Med Vasc* 2020;45:210–213. <https://doi.org/10.1016/j.jdmv.2020.04.008>
3. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2020;75:2950–2973. <https://doi.org/10.1016/j.jacc.2020.04.031>
4. Sharma RK, Stevens BR., Obukhov AG., Grant MB, Oudit GY, Li Q, et al. ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases. *Hypertension* 2020;76:651–661. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15595>
5. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc Res* 2020;116:1666–1687. <https://doi.org/10.1093/cvr/cvaa106>
6. Baum A, Schwartz MD. Admissions to Veterans Affairs Hospitals for Emergency Conditions During the COVID-19 Pandemic. *JAMA* 2020;324:96–99. <https://doi.org/10.1001/jama.2020.9972>
7. Georgakopoulos JR, Mufti A, Vender R, Yeung J. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study. *J Am Acad Dermatol* 2020;83:1212–1214. <https://doi.org/10.1016/j.jaad.2020.07.021>
8. ANSM : Agence nationale de sécurité du médicament et des produits de santé (2020) COVID-19 : disponibilité des médicaments et des produits de santé. 28/04/2020. <https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/COVID-19-l-ANSM-mobilisee-pour-assurer-la-disponibilite-des-medicaments-et-des-produits-de-sante-Point-d-information>
9. Lopes R, Van Gelder I, Hindricks G, Parati G. BRACE CORONA: Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19. In: ESC Congress 2020. <https://esc365.escardio.org/Congress/ESC-CONGRESS-2020-The-Digital-Experience/Hot-Line-BRACE-CORONA/31202-hot-line-brace-corona>.
10. Goffette P. Covid 19 : Enquête sur l'activité des médecins vasculaires - SNMV - Syndicat National des Médecins Vasculaires. In: 19<sup>ème</sup> congrès de la Société Française de Médecine Vasculaire. 17-19 septembre 2020, Bordeaux

**DISCLOSURE**

**Acknowledgements:** The authors thank the vascular physicians for their participation in this study.

**Conflicts of Interests:** The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding:** The French society of vascular medicine supported this work.

**Permission Information:** The authors do hereby declare that all illustrations and figures in the manuscript are entirely original and do not require reprint permission.

Journal Pre-proof

**Table 1.** Characteristics of patients

| Variables                                      | Values (n = 297) |
|--|------------------|
| Age (year +/- sd)                              | 65 +/- 14        |
| Female Sex (%)                                 | 56%              |
| Immobilization (lower limb trauma or bed rest) | 4%               |
|  |                  |
| Interruption of usual treatment (%)            | 5.0%             |
| Anticoagulant (%) for VTE                      | 2.0%             |
| Anticoagulant (%) for AF                       | 0.0%             |
| Antiplatelet agent (%)                         | 0.6%             |
| Antihypertensive drugs (%)                     | 0.6%             |
| Statin (%)                                     | 0.6%             |
| Anti-inflammatory (%)                          | 0.6%             |
| Anti-diabetic (%)                              | 0.3%             |
| Other (%)                                      | 0.3%             |

% : percentage, sd : standard deviation, VTE : Venous ThromboEmbolic disease, AF : Atrial Fibrillation